Shares of Abiomed Inc. (ABMD) rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use authorization from the Food and Drug Administration as a treatment for some COVID-19 patients. The heart pump can be used for patients who have heart or lung damage as a result of an infection with the coronavirus. This is the second time the FDA has authorized the pump for use in COVID-19 patients; in May, the FDA issued an EUA for patients suffering from COVID-19-related right ventricular complications. Abiomed's stock is up 80.7% year-to-date, while the S&P 500 is up 1.9%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
August 04, 2020 07:48 ET (11:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.